


# Erratum to: NK-Cell Immunotherapy for AML

Dean Anthony Lee, Laurence James Neil Cooper  
and Elizabeth J. Shpall

Erratum to:

Chapter 40 in: M. Andreeff (ed.), *Targeted Therapy of Acute Myeloid Leukemia*,  
Current Cancer Research, DOI 10.1007/978-1-4939-1393-0\_40

The Publisher regrets that in chapter 40, figure 40.1 is incorrect. The correct figure is given below.



**Fig. 40.1** The antileukemic benefit of KIR mismatch. NK cells in a donor who is heterozygous for HLA-C with respect to KIR ligands (having both a Group C1 allele that interacts with KIR2DL2 and a Group C2 allele that interacts with KIR2DL1) will be skewed toward no activation when receiving both inhibitory signals. However, when the NK cells are transferred to a recipient who is homozygous at HLA-C (e.g., HLA-C alleles are Group C1) the NK cells will lack the inhibitory signal through KIR2DL1, further tipping the balance toward activation when encountering tumor cells that also express activating ligands

The online version of the original chapter can be found under  
DOI 10.1007/978-1-4939-1393-0\_40

D. A. Lee (✉) · L. J. N. Cooper  
Division of Pediatrics Cell Therapy Section, The University of Texas MD Anderson Cancer  
Center, 1515 Holcombe Boulevard, Unit 0853, Houston, TX 77030, USA  
e-mail: dalee@mdanderson.org

L. J. N. Cooper  
e-mail: ljncooper@mdanderson.org

E. J. Shpall  
Department of Stem Cell Transplantation and Cellular Therapy, Division  
of Cancer Medicine, The University of Texas MD Anderson Cancer Center,  
1515 Holcombe Boulevard, Unit 0423, Houston, TX 77030, USA  
e-mail: eshpall@mdanderson.org